BORIS Regulates SOCS3 Expression Through Epigenetic Mechanisms in Human Hepatocellular Carcinoma Cells

HE Jing-yang, LIU Qiu-ying, WEI Ling. et al

Abstract

To study the regulation of suppressor of cytokine signaling 3 (SOCS3) expression bythe brother of the regulator of the imprinted site (BORIS) in hepatocellular carcinoma cell. Methods The expression of SOCS3 mRNA in HCC cell lines was detected by real-time quantitative PCR (qRT-PCR). The expression of SOCS3 protein in knockdown and overexpression BORIS of HCC cell lines was tested by Western blot. The SOCS3 gene promoter methylation statusin the knockdown and overexpression BORIS of hepatocarcinoma cell lines was detected by using methylation specific PCR (MSP-PCR) method. The potential BORIS binding site of SOCS3 promoter region was found by UCSC database analysis. The enrichment of BORIS in SOCS3 promoter region in endogenous high expression BORIS of HCC cells was evaluated by using chromatin immunoprecipitation (ChlP)-qPCR (ChlP-qPCR). The SOCS3 promoter region histone methylation status in the knockdown and overexpression BORIS of HCC was detected by ChlP-qPCR. Results The expression of SOCS3 mRNA in hepatocellular carcinoma cells was higher and SOCS3 protein expression was down-regulated or up-regulated in the knockdown or overexpression of BORIS mRNA hepatocarcinoma cells» so BORIS has a positive regulatory effect on SOCS 3 protein expression in hepatocarcinoma cells . MSP - PCR experiments showed that the SOCS 3 promoter in SMMC-7721 and HepG2 cells was unmethylated and knockdown of BORIS did not changc the methylation status; the SOCS3 promoter region of Huh7 cells was methylated; after overexpression of BORIS, the SOCS3 promoter region was changed to an unmethylated state; the SOCS3 promoter was unmethylated in HCCLM3, overexpression of BORIS did not alter the methylation status. The ChlP-qPCR assay demonstrated that BORIS specifically binds to the SOCS3 promoter region in HCC cells with high expression of BORIS. Histone methylation assay indicated that knockdown of BORIS reduced BORIS enrichment in the SOCS3 promoter region, with decreasing H3K4 me2 and increasing H3K27 me3 in the region of histone, whereas the overexpress BORIS in HCC cells showed the opposite situation. Conclusion BORIS plays a role of epigenetic regulationon SOCS3 gene promoter methylation and histone methylation, modulating the expression of SOCS3, and then involved in the development of hepatocellular carcinoma.

 

Keywords: Hepatocellular carcinoma BORIS, SOCS3, Epigenetic

 

Full Text:

PDF


References


FORNER A, LLOVET JM, BRUIX J. Hepatocellular carcinoma. Lancet.2012.379(9822): 1245-1255.

TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics,2012. CA Cancer J Clin,2015,65(2) :87-108.

SHI YH, DING WX, ZHOU J, et al. Expression of X- linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology,2008,48(2) :497-507.

HLADY RA, ZHOU D. PUSZYK W. et al. Initiation of aberrant DNA methylation patterns and heterogeneity in precancerous lesions of human hepatocellular cancer. Epigenetics, 2017,12 (3); 215-225.

WANG J, TANG X. WENG W. et al. The membrane protein melanoma cell adhesion molecule (MCAM) is a novel tumor marker that stimulates tumorigenesis in hepatocellular carcinoma. Oncogene.2015.34(47):5781 -5795.

HANDLE F. ERB HH. LUEF B. et al. SOCS3 modulates the response to enzalutamide and is regulated by androgen receptor signaling and CpG methylation in prostate cancer cells. Mol Cancer Res.2016.14(6):574-585.

GAO Y. Cl MICA V, REICH NC. Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3. J Biol Chem.2012,287(25) :20904-20912.

WU WY. KIM H, ZHANG CL, et al. Loss of suppressors of cytokine signaling 3 promotes aggressiveness in hepatocellular carcinoma. J Invest Surg. 2014, 27 ( 4 ); 197- 204.

STOFAS A. LEVIDOU G, PIPERI C, et al. The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma. BMC Cancer, 2014, 14: 149 [ 2017-02-21 ]. https://bmccancer. biomedcentral. com/articles/10. 1186/1471-2407-14-149. doi: 10. 1186/1471-2407-14-149.

HOAN NX, VAN TONG H, GIANG DP, et al. SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B. Oncotarget, 2017, 8; 17127-17139 [ 2017-09-21 ]. http://www. impactjournals. com/ oncotarget/index. php? journal = oncotarget 8-page = article&oP = view&-path%5b%5 d= 15083. doi; 10.18632/ oncotarget. 15083.

A LI О. CERJAK D. KENT JW Jr, et al. Methylation of SOCS3 is inversely associated with metabolic syndrome in an epigenome-wide association study of obesity. Epigenetics, 2016,11(9);699-707.

HUANG L. HU B, N1 J. et al. Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis. J Exp Clin Cancer Res, 2016, 35; 27 [ 2017-02-21 ]. https;//jeccr. biomedcentral. com,/ articles/10. 1186/sl3046-016-0301-7. doi; 10. 1186/si 304 6-016-0301-7.

LOUKINOV DI, PUGACHEVA E, VATOLIN S, et al. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11- zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A,2002,99(10):6806-6811.

DE NECOCHEA-CAMPION R, GHOCHIKYAN A, JOSEPHS SF, et al. Expression of the epigenetic factor BORIS (CTCFL) in the human genome. J Transl Med,2011, 9; 213 [ 2017-02-21 ]. https://translational-medicine. biomedcentral. com/articles/10. 1186/1479-5876-9-213. doi; 10. 1186/1479-5876-9-213.

BARRAGAN-HERNANDEZ M, et al. BORIS and CTCF are overexpressed in squamous intraepithelial lesions and cervical cancer. Genet Mol Res,2015,14(2) :6094-6100.

JOOSSESA, MULLER V, STEINBACH B, et al. Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases. Br J Cancer,2014 ,111(5): 909-917.

YOON SL, ROH YG, CHU IS, et al. A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility. Exp Mol Med, 2016, 48(7): e246 [2017-02-21]. http;//www. nature. com/emm/journal/v48/n7/full/emm201650a. lit ml. doi; 10. 1038/emm. 2016. 50.

TIFFENJC, BAILEY CG, MARSHALL AD, et al. The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells. Int J Cancer,2013,133(7): 1603-1613.

ZAMPIERI M, CICCARONE F, PALERMO R, et al. The epigenetic factor BORIS/CTCFL regulates the NOTCH3 gene expression in cancer cells. Biochim Biophys Acta,2014, 1839(9):813-825.

GAYKALOVA Г), VATAPALLI R, GLAZER CA, et al. Dose-dependent activation of putative oncogene SBSN by BORIS. PLoS One, 2012, 7(7): e40389 [ 2017-02-21 ]. http://dx. doi. org/10. 1371/journal, pone. 0040389.

LI Y, DEURING J, PEPPELENBOSCH MP, et al. IL-6- induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis,2012,33( 10) : 1889-1896.

NGUYEN P, BAR-SELA G, SUN L, et al. BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression. Mol Cell Biol,2008,28(21) ;6720-6729.

TAKEDA H. TAKAI A. INUZUKA T. et al. Genetic basis of hepatitis virus-associated hepatocellular carcinoma; linkage between infection, inflammation, and tumorigenesis. J Gastroenterol ,2017,52( 1): 26-38.

POTIKHA T, STOYANOV E, PAPPO O, et al. Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation-mediated hepatocarcinogenesis. Hepatology ,2013,58(1): 192-204.

BISHAYEE A. The role of inflammation and liver cancer. Adv Exp Med Biol, 2014, 816; 401-435 [ 2017-02-21 ]. https;//link, springer, com/chapter/10. 1007% 2F978-3- 0348-0837-8_16. doi; 10. 1007/978-3-0348-0837-8_16.

IN AG AKI-0 H A R A K. KONDO T. ITO M, et al. SOCS, inflammation, and cancer. JAKSTAT, 2013, 2 ( 3 ); e24053 [2017-02-21]. http://dx. doi. org/10. 4161/jkst. 24053. NIWA Y, KANDA H, SHIKAUCH1 Y. etui. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene, 2005, 24 ( 42 ); 6406- 6417.

MARTINEZ-QUETGLAS I, P1NYOI- R, DAUCH D, et al. IGF2 is up-regulated by epigenetic mechanisms in hepatocellular carcinomas and is an actionable oncogene product in experimental models. Gastroenterology, 2016 ,151 (6);1192-1205.

GAI X, TU K. LI C, et at. Histone acetyltransferase PCAF accelerates apoptosis by repressing a GLI1/BCL2/BAX axis in hepatocellular carcinoma. Cell Death Dis, 2015, 6 ; e 1712 [2017-02-21 ]. http://www. nature. com/cddis/journal/v6/ nl/full/cddis201576a. html. doi: 10. 1038/cddis. 2015. 76.

MONK M, HITCHINS M, HAWES S. Differential expression of the embryo/cancer gene ECSA ( DPPA2), the cancer/testis gene BORIS and the pluripotency structural gene OCT4, in human preimplantation development. Mol Hum Reprod,2008,14(6):347-355.


Refbacks

  • There are currently no refbacks.